RA Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

RA Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,611,733	Closed	-$219M	–	85
2026 Q1	$219M	Buy	2,611,733 +1,000,000	+62%	+$57.9M	2.32%	9
2025 Q4	$66.4M	Sell	1,611,733 -1,255,000	-44%	-$48.7M	0.68%	30
2025 Q3	$113M	Hold	2,866,733	–	–	1.39%	17
2025 Q2	$53.4M	Hold	2,866,733	–	–	0.9%	26
2025 Q1	$52M	Buy	2,866,733 +1,000,333	+54%	+$22M	0.87%	23
2024 Q4	$40.7M	Sell	1,866,400 -466,600	-20%	-$12M	0.54%	38
2024 Q3	$63.9M	Hold	2,333,000	–	–	0.74%	31
2024 Q2	$60.4M	Hold	2,333,000	–	–	0.8%	33
2024 Q1	$70M	Buy	+2,333,000	New	+$50.7M	0.89%	30
2022 Q4	–	Sell	-224,255	Closed	-$5.06M	–	73
2022 Q3	$5.06M	Buy	+224,255	New	+$6.14M	0.11%	69

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

RA Capital Management's DNTH Position: Q2 2026 in Review

RA Capital Management sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 2,611,733 shares — an estimated $219M sold.

RA Capital Management first reported a position in DNTH in Q3 2022 and held it in 10 quarters. The position peaked at $219M in Q1 2026. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

RA Capital Management reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
RA Capital Management sold 2,611,733 Dianthus Therapeutics shares in Q2 2026, an estimated $219M.
RA Capital Management first reported a position in Dianthus Therapeutics in Q3 2022 and held it in 10 quarters.
RA Capital Management's Dianthus Therapeutics position peaked at $219M in Q1 2026.
269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.